Search Results for "vol"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for vol. Results 651 to 660 of 1443 total matches.
A Stool DNA Test (Cologuard) for Colorectal Cancer Screening
The Medical Letter on Drugs and Therapeutics • Oct 13, 2014 (Issue 1453)
colonoscopy.
101
The Medical Letter ® Vol. 56 (1453) October 13, 2014
How often patients should be screened ...
The FDA has approved Cologuard (Exact Sciences),
a stool DNA test, to screen average-risk adults ≥50
years old for colorectal cancer.
Empagliflozin (Jardiance) for Diabetes
The Medical Letter on Drugs and Therapeutics • Oct 13, 2014 (Issue 1453)
in animals; no adequate
studies in women) for use during pregnancy.
100
The Medical Letter ® Vol. 56 (1453 ...
Empagliflozin (Jardiance – Boehringer Ingelheim/Lilly),
an SGLT2 inhibitor, has been approved by the FDA for
oral treatment of type 2 diabetes. It is the third SGLT2
inhibitor to be approved for this indication.
Vedolizumab (Entyvio) for Inflammatory Bowel Disease
The Medical Letter on Drugs and Therapeutics • Sep 15, 2014 (Issue 1451)
ulcerative colitis.5
87
The Medical Letter ® Vol. 56 (1451) September 15, 2014
Crohn’s Disease ...
The FDA has approved vedolizumab (Entyvio - Takeda),
an intravenous integrin receptor antagonist, for treatment
of moderate to severe ulcerative colitis or Crohn's
disease in adults who have not responded to, lost
response to, or cannot tolerate standard treatment.
Natalizumab (Tysabri), another integrin receptor antagonist,
has been available for several years for treatment
of Crohn's disease and multiple sclerosis.
Vorapaxar (Zontivity) for Prevention of Thrombotic Cardiovascular Events
The Medical Letter on Drugs and Therapeutics • Sep 15, 2014 (Issue 1451)
.
For further information call: 800-211-2769
86
The Medical Letter ® Vol. 56 (1451) September 15, 2014 ...
The FDA has approved vorapaxar (Zontivity – Merck), an
oral protease-activated receptor-1 (PAR-1) antagonist,
for use with aspirin and/or clopidogrel to reduce the risk
of thrombotic cardiovascular events in patients with
peripheral arterial disease or a history of myocardial
infarction (MI). It is the first PAR-1 antagonist to be
approved by the FDA.
Efinaconazole Topical Solution (Jublia) for Onychomycosis
The Medical Letter on Drugs and Therapeutics • Sep 15, 2014 (Issue 1451)
Letter ® Vol. 56 (1451) September 15, 2014
studies was achieved in about 55% of patients treated ...
The FDA has approved efinaconazole 10% solution
(Jublia – Valeant) for topical treatment of toenail
onychomycosis due to Trichophyton rubrum and/or
Trichophyton mentagrophytes. It is the first topical
triazole antifungal drug to be approved for this
indication. A topical oxaborole antifungal solution,
tavaborole 5% (Kerydin – Anacor), also recently
approved by the FDA for the same indication will be
reviewed in a future issue.
Miltefosine (Impavido) for Leishmaniasis
The Medical Letter on Drugs and Therapeutics • Sep 15, 2014 (Issue 1451)
The Medical Letter ® Vol. 56 (1451) September 15, 2014
who took miltefosine daily for 28 days had complete ...
The FDA has approved miltefosine (Impavido – Knight
Therapeutics), an oral alkylphosphocholine analog,
for treatment of visceral, cutaneous, and mucosal
leishmaniasis caused by some Leishmania species.
It is the first drug to be approved by the FDA for
treatment of cutaneous and mucosal leishmaniasis
and the first oral drug to be approved for treatment of
visceral leishmaniasis.
Statins and Diabetes Risk
The Medical Letter on Drugs and Therapeutics • Sep 01, 2014 (Issue 1450)
The Medical Letter ® Vol. 56 (1450) September 1, 2014
the Women’s Health Initiative who were followed ...
In 2012, the FDA required manufacturers of HMG-CoA
reductase inhibitors (statins) to add a warning to their
labels about reports of increased blood glucose and
glycosylated hemoglobin (HbA1c) levels. Since then,
several new studies have been published.
Two New Drugs for Skin and Skin Structure Infections
The Medical Letter on Drugs and Therapeutics • Aug 18, 2014 (Issue 1449)
dosage is 10-15 mg/kg q6h.
The Medical Letter ® Vol. 56 (1449) August 18, 2014
to another glycopeptide ...
The FDA has approved two new drugs for treatment
of adults with acute bacterial skin and skin structure
infections caused by susceptible gram-positive
bacteria. Dalbavancin (Dalvance – Durata) is a long-acting
intravenous (IV) lipoglycopeptide antibiotic
similar to telavancin (Vibativ). Tedizolid phosphate
(Sivextro – Cubist) is an IV and oral oxazolidinone
antibacterial drug similar to linezolid (Zyvox). A
third IV antibiotic, oritavancin (Orbactiv), recently
approved by the FDA for the same indication, will be
reviewed in a future...
Sucroferric Oxyhydroxide (Velphoro) for Hyperphosphatemia
The Medical Letter on Drugs and Therapeutics • Aug 18, 2014 (Issue 1449)
before swallowing.
74
The Medical Letter ® Vol. 56 (1449) August 18, 2014
sucroferric oxyhydroxide ...
Most patients with end-stage renal disease develop
hyperphosphatemia, which can lead to secondary hyperparathyroidism,
vascular calcification, and cardiovascular
mortality. The FDA has approved sucroferric oxyhydroxide
(Velphoro – Fresenius Medical Care), a chewable
phosphate binder, for treatment of hyperphosphatemia in
patients with chronic kidney disease (CKD) on dialysis. It
is the first iron-based phosphate binder to be approved for
this indication.
A Transcutaneous Electrical Nerve Stimulation Device (Cefaly) for Migraine Prevention
The Medical Letter on Drugs and Therapeutics • Aug 18, 2014 (Issue 1449)
.
74
The Medical Letter ® Vol. 56 (1449) August 18, 2014
1. Approximate cost according ...
The FDA has approved the use of a transcutaneous
electrical nerve stimulation device (Cefaly – Cefaly
Technology) for prevention of episodic migraine in
patients ≥18 years old. The first device to be approved
in the US for migraine prevention, it is available in
Canada and Europe for treatment and prevention of
migraines. A transcranial magnetic stimulation device
(SpringTMS - eNeura Therapeutics) recently approved
by the FDA for treatment of migraine preceded by aura
will be reviewed in a future issue.